Investors
Corporate Profile
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from GSDIa, phenylketonuria (PKU), Wilson disease, and citrullinemia; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in OTC deficiency, which is in a Phase 1/2 clinical trial. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Presentations
DateTitle
08/18/17
Dimension Therapeutics Corporate Presentation August 2017
Download Documentation
Stock
DMTX (Common Stock) $5.90 + 0.05 (0.85%)
High $5.90
Events
Dimension Therapeutics Q4 2016 Earnings and Corporate Update Conference Call
03/09/17 8:30 a.m. ET
E-mail Alerts
Sign up to receive
E-mail Alerts
 
News
September 19, 2017
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
Dimension to Begin Discussions with Ultragenyx CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, announced today that its Board of Directors has determined in good faith, after consultation with its financial advisor and outside legal counsel, that the non-binding, unsolicited proposal from Ultr[...]  Read More /
September 18, 2017
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX) (“Dimension”), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-binding, unsolicited proposal from Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) (“Ultragenyx”) to acquire Dimension for $5.50 per share in cash to be effectuated via a tender offer. Ultragen[...]  Read More /
August 31, 2017
Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency
Twelve trial sites recruiting patients with OTC deficiency in the United States, United Kingdom, Spain, and Canada Initial data from the company’s Phase 1/2 study anticipated by late 2017 CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the initiation of patient dosing in the company’s [...]  Read More /
Data provided by Nasdaq. Minimum 15 minutes delayed.